Overview

Ivermectin for Severe COVID-19 Management

Status:
Completed

Trial end date:
2020-09-02

Target enrollment:

Participant gender:

Summary

In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause side effects.

Phase:

Phase 3

Details

Lead Sponsor:

Afyonkarahisar Health Sciences University

Collaborator:

NeuTec Pharma

Treatments:

Azithromycin
Favipiravir
Hydroxychloroquine
Ivermectin